vs
Orthofix Medical Inc.（OFIX）与EXPRO GROUP HOLDINGS N.V.（XPRO）财务数据对比。点击上方公司名可切换其他公司
EXPRO GROUP HOLDINGS N.V.的季度营收约是Orthofix Medical Inc.的1.7倍（$382.1M vs $219.9M），EXPRO GROUP HOLDINGS N.V.净利率更高（1.5% vs -1.0%，领先2.5%），Orthofix Medical Inc.同比增速更快（2.0% vs -12.5%），EXPRO GROUP HOLDINGS N.V.自由现金流更多（$23.2M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -0.2%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Expro是一家能源服务提供商，总部位于美国得克萨斯州休斯敦，主要为油气等能源领域的客户提供相关技术服务与解决方案，业务覆盖全球多个主要能源产区，助力行业实现高效、安全的开发运营。
OFIX vs XPRO — 直观对比
营收规模更大
XPRO
是对方的1.7倍
$219.9M
营收增速更快
OFIX
高出14.5%
-12.5%
净利率更高
XPRO
高出2.5%
-1.0%
自由现金流更多
XPRO
多$6.4M
$16.8M
两年增速更快
OFIX
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $382.1M |
| 净利润 | $-2.2M | $5.8M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 3.1% |
| 净利率 | -1.0% | 1.5% |
| 营收同比 | 2.0% | -12.5% |
| 净利润同比 | 92.4% | -74.9% |
| 每股收益（稀释后） | $-0.05 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXXPRO
| Q4 25 | $219.9M | $382.1M | ||
| Q3 25 | $205.6M | $411.4M | ||
| Q2 25 | $203.1M | $422.7M | ||
| Q1 25 | $193.6M | $390.9M | ||
| Q4 24 | $215.7M | $436.8M | ||
| Q3 24 | $196.6M | $422.8M | ||
| Q2 24 | $198.6M | $469.6M | ||
| Q1 24 | $188.6M | $383.5M |
净利润OFIXXPRO
| Q4 25 | $-2.2M | $5.8M | ||
| Q3 25 | $-22.8M | $14.0M | ||
| Q2 25 | $-14.1M | $18.0M | ||
| Q1 25 | $-53.1M | $13.9M | ||
| Q4 24 | $-29.1M | $23.0M | ||
| Q3 24 | $-27.4M | $16.3M | ||
| Q2 24 | $-33.4M | $15.3M | ||
| Q1 24 | $-36.0M | $-2.7M |
毛利率OFIXXPRO
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXXPRO
| Q4 25 | 0.2% | 3.1% | ||
| Q3 25 | -8.3% | 6.4% | ||
| Q2 25 | -7.9% | 7.7% | ||
| Q1 25 | -25.2% | 2.6% | ||
| Q4 24 | -5.3% | 7.3% | ||
| Q3 24 | -9.6% | 6.2% | ||
| Q2 24 | -12.5% | 5.9% | ||
| Q1 24 | -15.6% | 2.2% |
净利率OFIXXPRO
| Q4 25 | -1.0% | 1.5% | ||
| Q3 25 | -11.1% | 3.4% | ||
| Q2 25 | -6.9% | 4.3% | ||
| Q1 25 | -27.4% | 3.6% | ||
| Q4 24 | -13.5% | 5.3% | ||
| Q3 24 | -13.9% | 3.8% | ||
| Q2 24 | -16.8% | 3.3% | ||
| Q1 24 | -19.1% | -0.7% |
每股收益（稀释后）OFIXXPRO
| Q4 25 | $-0.05 | $0.05 | ||
| Q3 25 | $-0.57 | $0.12 | ||
| Q2 25 | $-0.36 | $0.16 | ||
| Q1 25 | $-1.35 | $0.12 | ||
| Q4 24 | $-0.76 | $0.20 | ||
| Q3 24 | $-0.71 | $0.14 | ||
| Q2 24 | $-0.88 | $0.13 | ||
| Q1 24 | $-0.95 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $196.1M |
| 总债务越低越好 | — | $79.1M |
| 股东权益账面价值 | $450.0M | $1.5B |
| 总资产 | $850.6M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.05× |
8季度趋势，按日历期对齐
现金及短期投资OFIXXPRO
| Q4 25 | $82.0M | $196.1M | ||
| Q3 25 | $62.9M | $197.9M | ||
| Q2 25 | $65.6M | $206.8M | ||
| Q1 25 | $58.0M | $179.3M | ||
| Q4 24 | $83.2M | $183.0M | ||
| Q3 24 | $30.1M | $165.7M | ||
| Q2 24 | $26.4M | $133.5M | ||
| Q1 24 | $27.0M | $163.2M |
总债务OFIXXPRO
| Q4 25 | — | $79.1M | ||
| Q3 25 | $157.2M | $99.1M | ||
| Q2 25 | $157.0M | $121.1M | ||
| Q1 25 | $156.9M | $121.1M | ||
| Q4 24 | $157.0M | $121.1M | ||
| Q3 24 | $118.5M | $121.1M | ||
| Q2 24 | $118.0M | $121.1M | ||
| Q1 24 | $118.2M | $40.0M |
股东权益OFIXXPRO
| Q4 25 | $450.0M | $1.5B | ||
| Q3 25 | $442.5M | $1.5B | ||
| Q2 25 | $458.3M | $1.5B | ||
| Q1 25 | $458.3M | $1.5B | ||
| Q4 24 | $503.1M | $1.5B | ||
| Q3 24 | $525.9M | $1.5B | ||
| Q2 24 | $546.0M | $1.5B | ||
| Q1 24 | $570.3M | $1.3B |
总资产OFIXXPRO
| Q4 25 | $850.6M | $2.3B | ||
| Q3 25 | $832.6M | $2.3B | ||
| Q2 25 | $837.2M | $2.3B | ||
| Q1 25 | $823.1M | $2.3B | ||
| Q4 24 | $893.3M | $2.3B | ||
| Q3 24 | $867.9M | $2.3B | ||
| Q2 24 | $882.0M | $2.3B | ||
| Q1 24 | $906.0M | $2.0B |
负债/权益比OFIXXPRO
| Q4 25 | — | 0.05× | ||
| Q3 25 | 0.36× | 0.07× | ||
| Q2 25 | 0.34× | 0.08× | ||
| Q1 25 | 0.34× | 0.08× | ||
| Q4 24 | 0.31× | 0.08× | ||
| Q3 24 | 0.23× | 0.08× | ||
| Q2 24 | 0.22× | 0.08× | ||
| Q1 24 | 0.21× | 0.03× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $57.1M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $23.2M |
| 自由现金流率自由现金流/营收 | 7.6% | 6.1% |
| 资本支出强度资本支出/营收 | 4.9% | 8.9% |
| 现金转化率经营现金流/净利润 | — | 9.89× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $97.8M |
8季度趋势，按日历期对齐
经营现金流OFIXXPRO
| Q4 25 | $27.7M | $57.1M | ||
| Q3 25 | $12.4M | $63.2M | ||
| Q2 25 | $11.6M | $48.4M | ||
| Q1 25 | $-18.4M | $41.5M | ||
| Q4 24 | $23.7M | $97.4M | ||
| Q3 24 | $11.7M | $55.3M | ||
| Q2 24 | $9.0M | $-13.2M | ||
| Q1 24 | $-18.6M | $29.9M |
自由现金流OFIXXPRO
| Q4 25 | $16.8M | $23.2M | ||
| Q3 25 | $2.5M | $39.0M | ||
| Q2 25 | $4.5M | $27.2M | ||
| Q1 25 | $-25.1M | $8.4M | ||
| Q4 24 | $15.2M | $53.0M | ||
| Q3 24 | $6.3M | $23.3M | ||
| Q2 24 | $-360.0K | $-49.5M | ||
| Q1 24 | $-29.1M | $-801.0K |
自由现金流率OFIXXPRO
| Q4 25 | 7.6% | 6.1% | ||
| Q3 25 | 1.2% | 9.5% | ||
| Q2 25 | 2.2% | 6.4% | ||
| Q1 25 | -13.0% | 2.1% | ||
| Q4 24 | 7.0% | 12.1% | ||
| Q3 24 | 3.2% | 5.5% | ||
| Q2 24 | -0.2% | -10.5% | ||
| Q1 24 | -15.4% | -0.2% |
资本支出强度OFIXXPRO
| Q4 25 | 4.9% | 8.9% | ||
| Q3 25 | 4.8% | 5.9% | ||
| Q2 25 | 3.5% | 5.0% | ||
| Q1 25 | 3.5% | 8.5% | ||
| Q4 24 | 4.0% | 10.2% | ||
| Q3 24 | 2.7% | 7.6% | ||
| Q2 24 | 4.7% | 7.7% | ||
| Q1 24 | 5.6% | 8.0% |
现金转化率OFIXXPRO
| Q4 25 | — | 9.89× | ||
| Q3 25 | — | 4.52× | ||
| Q2 25 | — | 2.69× | ||
| Q1 25 | — | 2.98× | ||
| Q4 24 | — | 4.23× | ||
| Q3 24 | — | 3.40× | ||
| Q2 24 | — | -0.86× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
XPRO
| NLA | $130.3M | 34% |
| ESSA | $116.3M | 30% |
| MENA | $93.0M | 24% |
| Other | $42.5M | 11% |
